This review summarizes the current knowledge of oncogenic STAT3 and STAT5 functions in hematopoietic cancers as well as advances in preclinical and clinical development of pharmacological inhibitors. This evidence concerns the gene STAT5A and hematopoietic and lymphoid cell neoplasm.